Skip to Main Content

Paper Details

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
Nat Med
36
2022
APC, IGF2, KRAS, KRAS mutations, L1CAM, Locally advanced rectal cancer, RNA, distal, microsatellite, patients, rectal cancer, rectal cancers, tumors
Author NameAffiliation
Walid K ChatilaMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Walid K ChatilaMemorial Sloan Kettering Cancer Center
Walid K ChatilaTri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College
Ritika KundraMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Ritika KundraMemorial Sloan Kettering Cancer Center
Qian ShiMayo Clinic
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Francisco VegaMemorial Sloan Kettering Cancer Center
Francisco VegaMemorial Sloan Kettering Cancer Center
Francisco VegaColorectal Cancer Research Center, Memorial Sloan Kettering Cancer Center
  • 1 - 16

Datasets

Release 1.2